ClinicalTrials.gg
Active, not recruitingNCT05565443Updated Nov 4, 2026

MR-guided Focused Ultrasound Plus GCase

An interventional study of Blood Brain Barrier Disruption - Functional in Parkinsons Disease, sponsored by InSightec. Active, not recruiting at 1 site in Canada. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by InSightec · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Now Active, not recruitingPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Parkinson Disease by InSightec — 3 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · InSightec.

Planned enrollment
10th of 16
14 · median 20
Started
2022
with 1 other
No phase
16 of 19
1 open now
Registered
16th of 19
by date

Among the 19 studies in Parkinson Disease by InSightec, this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2022, is one of 16 with no phase, and was the 16th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 19 studies in Parkinson Disease by InSightec are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Parkinson Disease by InSightec, or all of them as a file.
02

Study summary

The goal of this study is to establish safety and feasibility of intracerebral delivery of GCase via MRgFUS. This technique may offer potential benefits given the exposure of the putamen to GCase in animal models has been shown to be efficacious in improving Parkinson's disease pathology and phenotype.

Read the detailed description

This is a two-arm, open-label, intervention only phase I/II clinical study. One arm of the study will enroll seven (7) GBA PD patients and the other arm seven (7) idiopathic PD patients. During the intervention phase, the first four subjects of each arm will receive three transcranial bilateral putamenal GCase at 30 IU/kg IV every two weeks, followed by 60 IU/kg in the next three subjects. Following three treatments in this study, the subjects will be followed for twelve months.

03

Conditions studied

  • Parkinsons Disease

Browse trials for

Keywords

  • Parkinson's disease
  • Glucocerebrosidase
  • GCase
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women between age 35 and 80 years, inclusive.
  • Able and willing to give .
  • Diagnosis of PD satisfying MDS Clinical Diagnostic Criteria for PD
  • At least 2 years from initial diagnosis
  • Hoehn and Yahr Stage 1-3 on PD medication
  • Dopaminergic deficit by a positive DAT SPECT scan
  • On stable regimen of PD medications for at least 90 days prior to the study
  • (ASA) score 1-3
  • Harbor at least one GBA mutation if enrolled in the GBA PD arm or two wild-type GBA alleles if enrolled in the idiopathic PD arm

Exclusion criteria

Exclusion Criteria:

  • Positive pregnancy test (for pre-menopausal women).
  • to DEFINITY ultrasound contrast agent or perflutren (e.g. , known left or bidirectional cardiac shunt)
  • Contraindication to MRI or gadolinium-DTPA (e.g. incompatible device, hypersensitivity)
  • Insulin-dependent diabetes mellitus that is not well-controlled or that in the Investigator's opinion precludes participation in the study.
  • Severely impaired renal function with estimated \<30 mL/min/1.73m2 and/or on dialysis.
  • Currently participating in another clinical therapeutic trial
  • Patient receiving bevacizumab (Avastin) therapy
  • Subjects with evidence of cranial or systemic infection.
  • Cerebral or systemic vasculopathy.
  • Documented cerebral infarction within the past 12 months or in the past 1 month.
  • Contraindication to GCase enzyme therapy, specifically previous hypersensitivity reaction to GCase enzyme therapy
  • Parkinsonism plus symptoms, secondary parkinsonism
  • Previous neurosurgical procedure for PD
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Idiopathic PD Patients

    Idiopathic PD patients receiving 3 cycles of BBBO. There is option to include simultaneous GCase delivery after safety profile review by Data and Safety Monitoring Board (DSMB).

    Device: Blood Brain Barrier Disruption - Functional

  • Experimental
    GBA PD Patients

    GBA PD patients receiving 3 cycles of BBBO. There is option to include simultaneous GCase delivery after safety profile review by Data and Safety Monitoring Board (DSMB).

    Device: Blood Brain Barrier Disruption - Functional

Interventions

  • DeviceBlood Brain Barrier Disruption - Functional

    Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Measure of the adverse events through the intervention phase and follow-up. All adverse events and/or Serious Adverse Events will be documented and reported according to CTCAE criteria.

    Time frame: 12 Months

Secondary outcomes

  1. Feasibility of MRgFUS BBB opening for GCase brain delivery

    Using MRI images to measure: 1. The qualitative measure of the MRI T1-weighted with gadolinium of contract extravasation in the sonicate putamen. 2. The qualitative measure of the dynamic contrast enhanced (DCE) MRI

    Time frame: 12 Months

07

Study locations

1 site
  • Sunybrook Research Institute
    Toronto, Ontario, Canada
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 47 months after the start.

Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's planned 47 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Nov 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2022
First posted
Oct 4, 2022
StartActual
Nov 30, 2022
Primary completionEst.
Nov 1, 2026was Dec 2027
CompletionEst.
Dec 31, 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 4, 2026
Primary completion
Dec 31, 2027→Nov 1, 2026
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 31, 2027→Nov 1, 2026
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05565443
Lead sponsor
InSightec
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Nov 30, 2022
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion